Associations - IDH1 mutation

BIOMARKER:

IDH1 mutation

Entrez ID:

3417

Related biomarkers:

Expression

Mutation

Others

‹

›

IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: A2 - Guideline Servier Press Release - 1 week ivosidenib Sensitive : A2 Servier Press Release - 1wk
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH1 mutation IDH1 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
IDH1 mutation IDH1 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials PCV Sensitive : B
IDH1 mutation IDH1 mutation	Glioma Glioma	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1
IDH1 mutation IDH1 mutation	Astrocytoma Astrocytoma	temozolomide Sensitive: C2 – Inclusion Criteria temozolomide Sensitive : C2
IDH1 mutation IDH1 mutation	Glioma Glioma	temozolomide Sensitive: C2 – Inclusion Criteria temozolomide Sensitive : C2
IDH1 mutation IDH1 mutation	Glioma Glioma	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine/daunorubicin liposomal formulation Sensitive : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	FT-2102 Sensitive: C3 – Early Trials FT-2102 Sensitive : C3
IDH1 mutation IDH1 mutation	Glioblastoma GBM	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
IDH1 mutation IDH1 mutation	Glioblastoma GBM	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3
IDH1 mutation IDH1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
IDH1 mutation IDH1 mutation	Glioma Glioma	BAY1436032 Sensitive: C3 – Early Trials BAY1436032 Sensitive : C3
IDH1 mutation IDH1 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials PCV Sensitive : C3
IDH1 mutation IDH1 mutation	Glioblastoma GBM	NEO100 Sensitive: C3 – Early Trials NEO100 Sensitive : C3
IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES